• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·EIKN
Held by 1 Guru
Share

Eikon Therapeutics, Inc. Stocks

$ 11.05Last Updated 14.08.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 598.23M

$ 11.05
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

08.02.2026 22:00

SpaceX, Syngenta and the "software apocalypse": the main thing about IPOs by February 8

05.02.2026 14:59

Eikon IPO: shares of the Merck veteran-led biotech become available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of EIKN is 25.3 and suggests 129% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.08.2026 01:09

Concerns over the Iran deal dragged U.S. stocks lower. Oil prices are back above $90.

18.08.2026 00:29

Trump threatened to "bomb" Oman if it interfered with U.S.-Iran talks

17.08.2026 23:40

Yields on long-term U.S. Treasury bonds have reached their highest level in nearly 20 years

17.08.2026 22:50

Nvidia will allocate up to $105 billion for an OpenAI data center. Is there a risk of circular schemes?

17.08.2026 22:31

Before the margin call, just two stocks made up the majority of the “AI Nostradamus” portfolio

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026